Attached files
| file | filename |
|---|---|
| 10-K/A - NORTHWEST BIOTHERAPEUTICS INC | v213223_10ka.htm |
| EX-31.1 - NORTHWEST BIOTHERAPEUTICS INC | v213223_ex31-1.htm |
| EX-32.1 - NORTHWEST BIOTHERAPEUTICS INC | v213223_ex32-1.htm |
CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
We
consent to the incorporation by reference into Registration Statement No.
333-134320 on Form S-1 and into Registration Statement No. 333-147579 on Form
S-8 of our report dated April 15, 2010, on our audit of the consolidated
financial statements of Northwest Biotherapeutics, Inc. and Subsidiary (a
development stage company) ("the Company") appearing in the Annual Report on
Form 10-K of Northwest Biotherapeutics, Inc. for the year ended
December 31, 2009.
Our
report, dated April 15, 2010, contains an explanatory paragraph that states
that the Company has experienced recurring losses from operations since
inception, has a working capital deficit, and has a deficit accumulated during
the development stage. These conditions raise substantial doubt about
the Company's ability to continue as a going concern. The
consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
|
/S/
PETERSON SULLIVAN LLP
|
|
|
Seattle,
Washington
|
|
|
March
1, 2011
|